Related Experiment Video

Updated: Apr 19, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.9K

miR30a inhibits LOX expression and anaplastic thyroid cancer progression

Myriem Boufraqech1, Naris Nilubol1, Lisa Zhang1

  • 1Endocrine Oncology Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Cancer Research
|December 10, 2014
PubMed

Insights

Downregulation of miR30a in anaplastic thyroid cancer (ATC) promotes tumor progression by increasing lysyl oxidase (LOX) expression. Targeting LOX may offer a new therapeutic strategy for this lethal malignancy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Anaplastic thyroid cancer (ATC) is a highly lethal malignancy with poorly understood genetic drivers.
  • MicroRNAs (miRNAs) play crucial roles in cancer development and progression.

Purpose of the Study:

  • To investigate the role of miR30a in anaplastic thyroid cancer (ATC).
  • To identify the downstream targets and mechanisms by which miR30a influences ATC progression.

Main Methods:

  • Quantitative real-time PCR to measure miR30a and lysyl oxidase (LOX) expression.
  • In vitro assays to assess cellular invasion, migration, and epithelial-mesenchymal transition (EMT).
  • In vivo metastasis assays and bioinformatic analysis to identify direct targets.

Main Results:

  • miR30a expression was significantly downregulated in ATC compared to differentiated thyroid cancer and normal thyroid tissue.
  • Downregulation of miR30a correlated with advanced disease and higher mortality.
  • miR30a directly targeted and suppressed LOX expression; LOX was upregulated in ATC and associated with poor prognosis.
  • Restoring miR30a reduced cellular invasion, migration, and EMT markers, while inhibiting LOX promoted these processes.

Conclusions:

  • Loss of miR30a expression is a critical event in ATC progression, leading to increased LOX expression and enhanced metastatic potential.
  • LOX is identified as a key mediator of miR30a's tumor-suppressive function in thyroid cancer.
  • Targeting the miR30a-LOX axis represents a potential therapeutic strategy for anaplastic thyroid cancer.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
25.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K